长春瑞滨单药治疗老年晚期非小细胞肺癌的临床研究

目的观察和评价长春瑞滨(NVB)单药治疗老年晚期非小细胞肺癌的临床疗效和毒性反应。方法21例晚期非小细胞肺癌患者均经病理组织学和(或)细胞学检查确诊。国产长春瑞滨(盖诺)25 mg/m2加NS100 ml快速静脉点滴,第1、8天。21 d为一个周期,至少治疗2个周期。结果21例患者均可评价,CR 1例,PR 5例,SD 6例,患者的近期有效率28.6%,TTP 5.1个月,中位生存期7.2个月,1年生存率30.1%。最主要的毒副反应为白细胞及血小板的降低,但均可以耐受。结论长春瑞滨(NVB)单药治疗老年晚期非小细胞肺癌有较好的临床疗效,可改善患者的生存质量,延长生存时间,毒性反应比较轻,老年患者亦可以耐受。

Clinical study of vinorelbine monotherapy in the treatment of advanced non-small cell lung cancer in the elderly

Objective To observe the efficacy,toxicity and side effects of vinorelbine monotherapy in the treatment of advanced non-small cell lung cancer in the elderly.Method Twenty-one elder patients with advanced non-small cell lung cancer were treated with vinorelbine.The efficacy was estimated after 2 cycles.Results Complete remisson(CR) was observed in 1 case,PR in 5 cases and SD in 6 cases,the response rate,time to progress(TTP),median survival time(MST) and 1-year survival rate were 28.6%,5.1 months,7.2 months and 30.1% respectively.The toxicity and side effects were leucopenia and thrombocytopenia,but they were tolerable.Conclusion Vinorelbine monotherapy in the treatment of the elderly with advanced non-small cell lung cancer is effective,safe and well tolerable.It can relieve the symptoms,improve quality of life and prolong the survival time.Elder patients were willing to receive it.